Lipocine presents LPCN 2101 posters at AES meeting; no specific data disclosed

Lipocine Inc.

Posters for LPCN 2101, a GABA A receptor PAM candidate for epilepsy, presented at AES Annual Meeting Dec 5-9, 2025.
Poster 99.1 covers clinical PK and tolerability; Poster 99.2 covers oral toxicokinetics for women with epilepsy.
No efficacy, safety, or numerical results included in the filing; exhibits referenced but not detailed.
LPCN 2101 is a novel oral neuroactive steroid anti-seizure medication candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.